Dermatological Drugs - United States

United States

The projected revenue in the Dermatological Drugs market in the United States is expected to reach €10.82bn in 2024.
It is anticipated that the revenue will continue to grow at an annual rate of 5.48% between 2024 and 2029.
This growth rate would result in a market volume of €14.13bn by 2029.
When compared to other countries worldwide, United States is expected to generate the highest revenue in the Dermatological Drugs market, with an estimated €10.82bn in 2024.
The United States is witnessing a surge in demand for dermatological drugs due to the increasing prevalence of skin conditions and the rising awareness about skincare.

Key regions: United Kingdom, Canada, Japan, Europe, China

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The demand for dermatological drugs in the United States has been steadily increasing over the years.

Customer preferences: The increasing prevalence of skin diseases, such as psoriasis, eczema, and acne, has led to a growing demand for dermatological drugs in the United States. Additionally, the growing awareness about the importance of maintaining healthy skin has also contributed to the growth of the market.

Trends in the market: One of the major trends in the dermatological drugs market in the United States is the increasing use of biologics. Biologics are drugs made from living cells and are used to treat a variety of skin conditions. They are becoming increasingly popular due to their effectiveness and fewer side effects compared to traditional drugs.Another trend in the market is the growing demand for topical drugs. Topical drugs are applied directly to the affected area and are effective in treating a variety of skin conditions, including acne, psoriasis, and eczema. They are preferred by patients due to their ease of use and fewer side effects compared to oral medications.

Local special circumstances: The United States has a well-established healthcare system that provides access to a wide range of dermatological drugs. Additionally, the country has a large population of aging individuals who are more prone to skin conditions, which has contributed to the growth of the market.

Underlying macroeconomic factors: The United States has a strong economy and high levels of disposable income, which has allowed individuals to spend more on healthcare, including dermatological drugs. Additionally, the country has a well-established pharmaceutical industry that is constantly developing new and innovative drugs to treat a variety of skin conditions.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.